We leverage gold-standard technologies to investigate target engagement; potency of lead compounds, and their mode of action; and to enable a smooth transition to the clinic. Patient tissues are handled in our biobanks.
Novalix’s core indications include oncology, immuno-inflammation, infectious diseases, fibrosis, kidney diseases, osteoarthritis, metabolic disorders, and NASH.
Translational science
Disease-related targets include numerous GPCRs, enzymes, and epigenetic regulators.
Our complex in vitro, ex vivo assays and in vivo mechanistic models using rodent or human primary cells/organs/explants, coupled to a large technical platform enable:
- The assessment of the mechanism of action based on key parameters such as cell function, differentiation, pathway signaling, target and biomarker expression regulation.
- The translation of the mechanism of action in preclinical models and human disease samples.
- The determination of effective dose of lead compounds.
| Translational activities | Samples | Assay technologies |
|---|---|---|
| Mode of action: targeted cell(s) and their function, pathway analysis, biomarkers, omics analysis Understanding of effective dose: target engagement, pharmacodynamics, PK/PD Translation to human: target/pathway profiling, biomarkers, pre-clinical disease model characterization; in both rodent and human samples/models | Cell lines Primary cells: mouse, rat, human Whole blood, plasma, serum (mouse, rat, human) Mouse tissue explant Mouse and human skin explants Mouse tissues Biobank: human samples | Protein analysis: Jess, ELISA, AlphaLISA, Luminex, MSD, Simoa Gene expression and Omics: Viia7+, Ncounter, ddPCR, GeoMx, Chromium for single cell Flow cytometry: FACSLyric, Fortessa X20, Aurora, MA900 sorter |